CARGO Therapeutics, Inc. (CRGX)
(Delayed Data from NSDQ)
$17.85 USD
+0.15 (0.85%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $18.15 +0.30 (1.68%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth A Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CRGX 17.85 +0.15(0.85%)
Will CRGX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CRGX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRGX
What Makes CARGO Therapeutics, Inc. (CRGX) a New Buy Stock
Wall Street Analysts See a 56.26% Upside in CARGO Therapeutics, Inc. (CRGX): Can the Stock Really Move This High?
CRGX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Company News for Mar 25, 2024
Alexandria (ARE) to Post Q4 Earnings: What's in the Cards?
Alexandria (ARE) Inks Leases at its Campuses Amid Solid Demand
Other News for CRGX
Cargo Therapeutics initiated with bullish view at H.C. Wainwright, here's why
CARGO Therapeutics Announces Phase 1 Clinical Study of Firi-cel CAR T-Cell Therapy Published in The Lancet
CARGO Therapeutics’ Promising Pipeline and Market Potential Justify Buy Rating
Cargo Therapeutics initiated with bullish view at Piper Sandler, here's why
CARGO Therapeutics Adds Experienced Biopharma Executive to Board of Directors with the Appointment of Jane Pritchett Henderson as Independent Director